REDWOOD CITY, Calif., Dec. 6, 2022 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM) is committed to establishing gene therapy as a new standard of care for highly prevalent eye diseases. Aiming to be a company in the clinical stage. , announced the granting of stock options to new employees. On December 1, 2022, Adverum granted stock options to new employees to purchase 200,000 shares of Adverum common stock pursuant to an exception to incentives granted under Nasdaq Rule 5635(c)(4). Employment at Adverum. His exercise price per share of this option will be equal to the closing price of his Adverum common stock on his Nasdaq stock market on the date of grant, provided that the employee continues to work for her Adverum; Rights vest over four years.
About Adverum Biotechnologies
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company focused on the treatment of highly prevalent eye diseases, aiming to develop functional therapies for these diseases to restore vision and prevent blindness. We aim to establish gene therapy as a new standard. Adverum is designed to be delivered in the doctor’s office to leverage the research capabilities of its proprietary intravitreal (IVT) platform to eliminate the need for frequent eye injections to treat these diseases We are developing a long-lasting, single-dose therapy that Adverum will use its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly known as ADVM-022), as her one-time IVT injection for patients with neovascular or exudative age-related macular degeneration. was called). By overcoming the challenges associated with current treatment paradigms for these debilitating eye diseases, Adverum aims to transform the standard of care, preserve vision and create profound societal impact around the world. For more information, please visit www.adverum.com.
Inquiries from companies, investors and media
Vice President, Head of Corporate Strategy, External Affairs and Engagement
Adverum Biotechnologies, Inc.